Telix Pharmaceuticals Ltd (ASX:TLX; NASDAQ:TLX) concluded Friday's trading session at A$14.91, representing a decline of 8.36% over the preceding five trading sessions. The broader S&P/ASX 200 index slipped just 0.11% during the same period, highlighting Telix's significant underperformance relative to the benchmark.
On Friday alone, Telix shares dropped 4.48%, while the ASX 200 fell 0.50% to close at 8,796.70 points. Trading volume surged to 2.13 million shares, more than double the four-day average of 1.05 million, indicating heightened investor activity and possible distribution.
Investor sentiment was dampened by news that the company's 2026 revenue guidance of US$950 million to US$970 million includes only approved markets, with Japan conspicuously absent from the forecast. This exclusion underscores the uncertainty surrounding the conditional approval process for Illuccix in Japan.
Telix has enrolled 105 participants across 11 sites in its Phase 3 study in Japan, evaluating the sensitivity of PSMA-PET imaging against conventional CT and bone scans for detecting prostate cancer recurrence after surgery. The data will support a new drug application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
In March, the PMDA noted that no PSMA-PET agent had been approved in Japan for initial staging or recurrence detection. Japan is projected to see 99,900 new prostate cancer cases in 2025, though only a subset would be eligible for Telix's intended indication. A request for conditional approval is still under review, with no timeline for a decision.
Analyst sentiment remains mixed. RBC Capital Markets downgraded Telix from Outperform to Sector Perform on Friday, though it maintained a price target of A$18, implying a 20.7% upside from the close. The consensus of 14 analysts tracked by MarketScreener yields an average target of A$23.35, with a low of A$18. Every analyst target sits above the current market price, suggesting potential value but also acknowledging regulatory risk.
Telix projects 2026 research and development expenditure between US$200 million and US$240 million. Rapid regulatory progress in Japan would support this investment level, but approval remains the key hurdle. Risks include possible postponement or rejection of conditional approval, trial endpoint failures, and uncertainty around reimbursement and eligible patient demand.
Novartis AG (NYSE:NVS) secured Japanese approval for its PSMA-targeted agent Locametz in September 2025, but its label is limited to patient selection for therapy, not recurrence detection. This leaves a potential niche for Illuccix if approved.
David N. Cade, Telix's group chief medical officer, described the enrollment milestone as "a significant step towards the registration of Illuccix in Japan," noting rapid recruitment across multiple sites. The market, however, assigned minimal immediate value to the news in Friday's session.
